Back to top
Clinical stage:
In-vitro

The first sub-unit vaccine being investigated by N4 Pharma is a single dose reformulation of the existing Hepatitis B surface antigen vaccine (HBsAg) which had annual sales of approximately $920 million in 2012. The Company believes there is a commercial need for a single dose Hepatitis B vaccine. Nuvac (our nano-carrier delivery technology) is being used to develop this by reformulating the existing HBsAg vaccine.
 This project is currently on hold whilst the Company focuses on developing its Nuvec® platform.